ArticleACS omega2025
Integrative Multi-omics and Network Pharmacology Reveal the Mechanisms of Xiaoyaosan in Treating Depression.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Depression and Gastrointestinal Health Abnormalities: Treatment Approaches from the Perspective of Traditional Chinese Medicine.Neuropsychiatric disease and treatment · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the continued rise in the incidence and prevalence of depression globally, treatment options involving traditional Chinese medicine (TCM) are receiving increasing attention. Xiaoyaosan, which is commonly used to treat depression, has been used in clinical practice for more than 1000 years in China. Our previous research has confirmed that Xiaoyaosan (XYS), an herbal TCM prescription, can improve depressive-like behavior by regulating the gut microbes closely related to immune-inflammatory processes, providing a potential basis for the antidepressant actions of XYS. The aim of this research is to investigate the antidepressant mechanism of XYSspecifically, we examined the downregulation of the PI3K/Akt/mTOR signaling pathway, restoration of Th17/Tregs, and reduction of inflammatory responseusing network pharmacology, transcriptomics, 4D proteomics, molecular docking, molecular dynamics simulation, and animal experiments. The chemical components of XYS were obtained using the PubChem database and HERB. The ADMET lab 3.0 drug absorption, distribution, metabolism, excretion, and toxicity prediction tool was used to screen the potential ingredients of the compound. The Swiss Target Prediction and SEA TCM ingredient target prediction platforms were used to predict the targets of potential active ingredients. The STRING database was used for protein-protein interaction (PPI) network analysis of the target. A chronic immobilization stress (CIS) rodent model of depression was established using male Sprague-Dawley rats (
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.